An interventional study of SNAQ app and Traditional carbohydrate counting in Type 1 Diabetes, sponsored by Lia Bally. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Lia Bally · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 21st largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2023, is one of 25 with no phase, and was the 59th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
DCB Research AG · Sites in Switzerland
Ages 18–40 · Women only
Sanofi · Sites in Switzerland, United States, Argentina and 17 more countries
Ages 1–25
University of Bern · Sites in Switzerland
Ages 18–65
Pediatric Clinical Research Platform · Sites in Switzerland
Ages 0–25 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 16
First in 1997; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is close to the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 29 across the 52 interventional studies, 73 across the 18 observational. Of the 55 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 70 have an industry lead sponsor. The 10 most frequent:
Lia Bally is the lead sponsor of 15 studies on the registry; none are open to participants now.
Lia Bally has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus, Type 1 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05594706University Hospital, GenevaAnhydroglucitol in Children With Type 1 Diabetes | 2026-12-31 |
| NCT05791201Vertex Pharmaceuticals IncorporatedA Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | 2027-03-12 |
| NCT06282055DCB Research AGTrajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Carbohydrate count marks the cornerstone of Type 1 Diabetes management. Eventhough it is a crucial task, it is burdensome and prone to error. Therefore, the investigators want to explore the effect that SNAQ, a food analyser app would have in glycaemic control by facilitating the task of carbohydrate estimation.
Diet and physical activity are critically important in the lifestyle of people with type 1 diabetes. When diagnosed with the disease, people with type 1 diabetes are educated about nutritional goals and how to estimate nutritional content of food. Carbohydrates are the food component with the greatest impact on blood glucose levels and typical sources in the diet include starches, some vegetables, fruits, dairy products and sugars . Thus, people with type 1 diabetes are primarily being trained to estimate the carbohydrate content of food, a task that is also referred to as carbohydrate counting. Different methods can be used to count carbohydrate in food and drink. These include reading the nutritional labels, consulting reference books or websites, carrying a database on a personal digital assistant or using exchange tables which provides the carbohydrate content for typical serving sizes (e.g. 1 slice of bread). While nutritional information can be accessed through the above mentioned methods, the quantification of the portion sizes (if not indicated on the food package) requires the additional use of scale or measuring vessel. Given the required effort and time investment related to these methods, the great majority of people with type 1 diabetes count carbohydrates by visual estimation and experience. As a consequence, people's estimate often deviate substantially from ground truth values and average carbohydrate estimation errors reported in the literature are 20% or higher.
Of note, more than 60% of individuals with diabetes report having trouble with carbohydrate counting, despite their awareness on its importance . Even in patients who are confident in applying carbohydrate counting, the daily task is perceived as major burden of diabetes self-management.
Since carbohydrate counting is particularly demanding when eating fresh, non-packaged foods, a concerning trend towards unhealthy dietary choices with preference of prepackaged foods (with accessible nutrition facts) over whole foods is increasingly observed in people with type 1 diabetes. This is paralleled by an increasing prevalence of overweight and obesity in the type 1 diabetes population.
Thus, even with the latest hybrid closed-loop insulin delivery technologies, adequate nutrition knowledge remains a cornerstone for satisfactory glucose control, metabolic health, and prevention of diabetes-related complications and comorbidities.
With the development of new technologies embedded in modern smartphones (i.e. depth sensors), image-based methods to support food assessment have become widely available. Of particular use is the employment of well-established computer vision methodologies to estimate the quantity of food. When combined with food-recognition technologies and information from nutritional databases, a proposition of the nutritional content (e.g. carbohydrates, fat, proteins, fibres) can be made to the user on the basis of captured images and obviates the need for error prone visual estimations and mental calculations. Several such applications have become available and can support monitoring the diet as part of lifestyle management.
Insights from a recent online survey suggest that a high proportion of people with type 1 diabetes believe that such new technologies for meal management could facilitate their daily self-management and would be interested in using such technology. Moreover, according to a recent study, such digital tools may promote diabetes education and food literacy which may particularly benefit those with a lower education level and with a history of depression.
Amongst several options (e.g. Foodvisor, Calorie-Mamma, Lifesum) for image-based food tracking and analysis, SNAQ is one of the most commonly used app in people with type 1 diabetes. Up to date, more than 40000 users have downloaded the SNAQ app in their phones, of which 2,500 are living in Switzerland.
The investigators have previously demonstrated that the system estimates the macronutrient content of real meals with satisfying accuracy.
However, evidence with regards to the effect of the food analysis on daily self-management of people with type 1 diabetes (e.g. glucose control, meal patterns, perceived benefits) is currently lacking. The investigators therefore aim to address these aspects in a randomized-controlled study contrasting the use of the SNAQ app with people's traditional meal management techniques.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group will use SNAQ app for the first 3 weeks (baseline to V1) of the study.
Other: SNAQ app
The control group will continue estimating the carbohydrate count using their traditional methods for the first three weeks of the study (baseline to V1).
Other: Traditional carbohydrate counting
SNAQ is a smartphone food analysis app that estimates the macronutrient content of a meal, based on a single image. The app first determines meal content in terms of food components with input from the user to correct or add further components (e.g. foods, ingredients, sauces, herbs or seasonings). Then, the total macronutrient and energy content of the meal is determined based on the estimated volume and information from a nutritional database. Of note, the application also allows for assessing nutritional content of packaged foods by means of a barcode scanning function. The user can always adapt proposed nutritional contents at their own discretion. Meal macronutrients alongside the food pictures are collected in a detailed log which allows users to review their dietary choices. The product is not conceived by its manufacturer to be used for medical purposes and can thus not be considered a medical device.
Patients will follow their traditional methods of carbohydrate counting during the control period. In addition to assess sustainability of the intervention, following the control period, the control group will also go an intervention period of 3 weeks using the SNAQ App.
Percentage of time with sensor glucose in the target range
Percentage of time with sensor glucose in the target range between 3.9 to 10.0mmol/L, %
Time frame: 3-week intervention period (Day 1 to Day 21)
Percentage of time with sensor glucose in hyperglycaemia
Percentage of time with sensor glucose in the target range above 10.0mmol/L, %
Time frame: 3-week intervention period (Day 1 to Day 21)
Percentage of time with sensor glucose in hypoglycaemia
Percentage of time with sensor glucose in the target range below 3.9 mmol/L, %
Time frame: 3-week intervention period (Day 1 to Day 21)
Percentage of postprandial time with sensor glucose in target range
Percentage of postprandial time with sensor glucose in target range between 3.9 to 10.0 mmol/L
Time frame: 3-week intervention period (Day 1 to Day 21)
Percentage of postprandial time with sensor glucose in hyperglycaemia
Percentage of postprandial time with sensor glucose in the target range above 10.0mmol/L, %
Time frame: 3-week intervention period (Day 1 to Day 21)
Percentage of postprandial time with sensor glucose in hypoglycaemia
Percentage of postprandial time with sensor glucose in the target range below 3.9 mmol/L, %
Time frame: 3-week intervention period (Day 1 to Day 21)
Sustainability: Change in percentage of time with sensor glucose in the target range
Sustainability: Change in the percentage of time with sensor glucose in target range (3.9 to 10.0mmol/L, %)
Time frame: 2-3-weeks before period with intervention compared with the 3 weeks after intervention
Sustainability: Change in the percentage of time with sensor glucose in hyperglycaemia
Sustainability: Change in percentage of time with sensor glucose above target range (\>10.0mmol/L, %)
Time frame: 2-3-weeks before period with intervention compared with the 3 weeks after intervention
Sustainability: Change in the percentage of time with sensor glucose in hypoglycaemia
Sustainability: Change in percentage of time with sensor glucose below target range (\<3.9mmol/L, %)
Time frame: 2-3-weeks before period with intervention compared with the 3 weeks after intervention
Sustainability: Change in the percentage of time with postprandial sensor glucose in target range
Sustainability: Change in the percentage of time with postprandial sensor glucose in target range (3.9 to 10.0mmol/L, %)
Time frame: 2-3-weeks before period with intervention compared with the 3 weeks after intervention
Sustainability: Change in the percentage of time with postprandial sensor glucose in hyperglycaemia
Sustainability: Change in the percentage of time with postprandial sensor glucose above target range (\>10.0mmol/L, %)
Time frame: 2-3-weeks before period with intervention compared with the 3 weeks after intervention
Sustainability: Change in the percentage of postprandial time with sensor glucose in hypoglycaemia
Sustainability: Change in the percentage of postprandial time with sensor glucose below target range (\<3.9mmol/L, %)
Time frame: 2-3-weeks before period with intervention compared with the 3 weeks after intervention
Plan to share: Yes — Anonymised individual participant data will be shared after inquiry via a validated sharing platform (yet to be defined). Anonymised data packages will be available once the final study results are published in a peer-reviewed journal.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After publication of the study results in a peer-reviewed journal.
Access criteria: Contact with an approval by the corresponding author.
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in May 2024, 13 months.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 13 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lia Bally